Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_8ee0da6543d4d16f0634e75baf2d0d58 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-57527 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-575 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K14-585 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-16 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
filingDate |
2016-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5fe0f4a6cb6ae233d24db24f7b1bada7 |
publicationDate |
2016-11-17-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2016183479-A1 |
titleOfInvention |
Variants of adrenomedullin and calcitonin gene-related peptide and methods of use |
abstract |
Variant peptides of calcitonin gene-related peptide alpha (αCGRP), calcitonin gene-related peptide beta (βCGRP), and adrenomedullin (AM) are disclosed, wherein the variant peptides have high binding affinity and agonistic or antagonistic activity for at least one receptor complex of CLR:RAMP1, CLR:RAMP2, and CLR:RAMP3. Also disclosed are methods of use of the variant peptides in therapeutic treatments. |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-11390657-B2 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019005623-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2019087161-A1 |
priorityDate |
2015-05-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |